Dino Mustafić

January 7, 2019 Off

Adverum Biotechnologies has sufficient cash to fund operations at least through the first half of 2020, to advance Novel Gene Therapy ADVM-022 for Wet AMD in OPTIC Phase 1 clinical trial

Adverum Biotechnologies, a California-based ophthalmology and rare diseases focused biotech company, expects to provide an update on enrollment from the OPTIC phase 1 clinical trial in the first half of 2019, and interim data on the three cohorts from the OPTIC phase 1 clinical trial by the first quarter of 2020, it said in an outlook for 2019.

January 7, 2019 Off

Stelexis Therapeutics closes $43 million Series A financing

By Dino Mustafić

New York-based cancer therapeutics company, Stelexis Therapeutics has closed a $43 million Series A financing to expand its proprietary platform to discover and selectively target pre-cancerous stem cells.

January 7, 2019 Off

AstraZeneca pays $15 million to its partner Sosei Group, as it hits milestone in development of cancer candidate

By Dino Mustafić

AstraZeneca has reached a clinical development milestone with immuno-oncology candidate AZD4635, thus triggering a $15 million payment to its partner, Sosei Group.

January 7, 2019 Off

4D pharma to test its diverse cancer settings Live Biotherapeutic oncology pipeline with University of Texas MD Anderson Cancer Center

By Dino Mustafić

4D pharma and The University of Texas MD Anderson Cancer Center will together work on testing 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings, the company said on Monday in a press release

January 7, 2019 Off

Orexo’s nasal spray satisfied in test, turns to FDA for consultation

By Dino Mustafić

Orexo AB’s nasal spray formulations for opioid overdose reversal has been compared to Narcan in a study, in which it showed similar or better results, the company said in a press release on Monday.

January 7, 2019 Off

Sanofi to pay Regeneron $462 million as companies restructure immuno-oncology agreement for more independence in each research

By Dino Mustafić

Regeneron Pharmaceuticals and Sanofi restructure immuno-oncology agreement from 2015, where Regeneron retains full rights to all its other investigational immunooncology programsto, while Sanofi is able to independently chase own immuno-oncology programs.

January 7, 2019 Off

Neumentum’s study confirms investigational non-opioid pain treatment performing as predicted

By Dino Mustafić

Neumentum said Monday that findings from its phase I study of NTM-001 (pre-mixed bag ketorolac for continuous infusion), confirmed the investigational non-opioid pain treatment performs as it predicted in healthy adult volunteers.

January 7, 2019 Off

DiscGenics’ cell therapy IDCT passes the Initial Safety Review of its first-in-human clinical trial for degenerative disc disease

By Dino Mustafić

DiscGenics’s IDCT cell therapy has passed the initial planned safety review of its Phase I/II trial evaluating the allogeneic, injectable disc cell therapy in patients with mild to moderate degenerative disc disease (DDD).

January 7, 2019 Off

Schreiner MediPharm to present smart vial kit for digital therapy monitoring in Paris, at Pharmapack 2019

By Dino Mustafić

Schreiner MediPharm’s trade fair presentation at Pharmapack 2019 in Paris will be fully focused on smart packaging solutions. On February 6 and 7, in Hall 7.2, Booth B32, the specialist for innovative labels and marking solutions with value-added benefits will showcase its latest product development in the field of digital therapy monitoring: The new “Smart Vial Kit” enables electronic tracking and monitoring of medication dispensing and intake.

January 7, 2019 Off

F2G combines €24 million loan and investment from Chinese Morningside to speed up its fungal infections treatment candidate olorofim

By Dino Mustafić

A UK- and Austria-based Biotech company F2G Ltd, has raised funding from life science investor Morningside Venture Investments Ltd. (Morningside), after borrowing €24 million from the European Investment Bank (EIB) in November 2018 to speed up the phase 2 study for its lead candidate, a treatment for invasive fungal infections, olorofim.